Placeholder Banner

Advance Notice of Proposed Rulemaking: International Pricing Index Model for Medicare Part B Drugs

December 31, 2018

BIO strongly opposes the potential proposal detailed in the ANPRM and calls for withdrawal of the IPI model in its entirety, as:

  1. The IPI model is inconsistent with the charge of CMS’ Innovation Center, and does not appropriately consider benefit to the patient;
  2. The IPI model imports foreign price controls on American innovation, jeopardizing access to new medicines for Medicare’s vulnerable beneficiaries;
  3. The IPI model introduces new middlemen and complexity into providers’ delivery of critical medicines, potentially jeopardizing care to patients without reducing beneficiary costs; and
  4. The IPI model is part of broader Agency efforts that are eroding the value of the Medicare benefit for seniors and putting patient access to care at risk.

These concerns are described further in the balance of this comment letter.
 

Download Full Comments Below
FINAL IPI ANPRM BIO Comments 31 Dec 18 0
BIO's Comments on IPI ANPRM
Discover More
The Biotechnology Innovation Organization (“BIO”) would like to submit the following comments regarding FDA’s recent proposal to implement aspects of the Canadian importation provisions of Section 804 of the Food Drug & Cosmetics Act (“FD&C…
The Council of State Bioscience Associations (“CSBA”) appreciates the opportunity to submit the following comments regarding FDA’s recent proposal to implement aspects of the Canadian importation provisions of Section 804 of the Food Drug &…
The Biotechnology Innovation Organization provided comments to the Treasury Department and Internal Revenue Service on proposed regulations under Section 382 with respect to the built-in gain and built-in loss rules of Section 382(h).